# Rejuvenation Technologies Inc. — mRNA therapeutics to extend healthspan entering clinical trials

```yaml
url: "https://forg.to/companies/rejuvenation-technologies-inc"
website: "https://www.rejuvenationtech.com/"
industry: "Healthtech"
company_size: "1-10 employees"
headquarters: "San Francisco, USA"
is_hiring: false
open_roles: 0
verified: false
created: 2026-07-23
```

## About Rejuvenation Technologies Inc.

Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Extends mouse lifespan by equivalent of 10 years in humans. Reverses 5-10 years of telomere shortening with one dose in one day. Preclinical efficacy in 4 organ systems including immune system. Entering clinical stage. CEO is Subject #1 in longevity trial. 50+ granted patents, 7 patent families. FDA INTERACT cleared. Raising $10M seed extension ($2M+ wired) to fund 3 investigator-initiated trials. Readouts in Q3 2027. $6.8B in comparable mRNA-LNP M&A in last 12 months.

## Links

- Website: https://www.rejuvenationtech.com/
- Forg: https://forg.to/companies/rejuvenation-technologies-inc

---
Listed on [Forg](https://forg.to) — the professional network for builders

_HTML version: https://forg.to/companies/rejuvenation-technologies-inc_